IPCS INCHEM Home

International Agency for Research on Cancer (IARC) - Summaries & Evaluations

SULFAFURAZOLE

VOL.: 24 (1980) (p. 275)

5. Summary of Data Reported and Evaluation

5.1 Experimental data

Sulfafurazole was tested in mice and rats by oral administration: no increases in tumour incidences were observed.

No adequate studies of mutagenicity were available.

It is teratogenic for mice and rats.

5.2 Human data

Sulfafurazole is one of the most commonly used sulfonamide drugs in the treatment of urinary tract infections. Its production has remained stable during recent years.

In one hypothesis-seeking epidemiological study, no association was observed between sulfafurazole use and any cancer.

In two large studies of women exposed during pregnancy, no increase in malformation rate was observed in the offspring.

5.3 Evaluation

The data from studies in experimental animals and in humans were not indicative of a carcinogenic effect but were not sufficient for an evaluation of the carcinogenicity of sulfafurazole to humans.

Subsequent evaluation: Suppl. 7 (1987)


Last updated: 7 April 1998






















    See Also:
       Toxicological Abbreviations